13-Cis Retinoic Acid Induces Neuronal Differentiation in Daoy (Medulloblastoma) Cells Through Epigenetic Regulation of Topoisomerase IIβ

被引:0
作者
Jing Chen
Jing-Xia Zhang
Hai-Xia Lei
Xing-Yu Li
Yong-Xin Yan
Yan-Ling Wang
Yu-Hong Lv
Yun-Li Yan
Yu-Hua Lei
机构
[1] Hebei Medical University,Department of Cell Biology, College of Basic Medicine
[2] Shijiazhuang Second Hospital,Department of Radiology
[3] Hebei General Hospital,Department of Oncology
来源
Applied Biochemistry and Biotechnology | 2023年 / 195卷
关键词
13-cis RA; Top IIβ; H3K27me3; JMJD3; Daoy cell; Neuronal differentiation;
D O I
暂无
中图分类号
学科分类号
摘要
Medulloblastoma (MB) is a malignant tumor of the cerebellum that occurs in children and infants. Abnormal neuronal differentiation can lead to brain tumors, and topoisomerase IIβ (Top IIβ) plays an important role in neuronal differentiation. The aim of this study was to investigate the molecular mechanism of 13-cis retinoic acid (13-cis RA) promoting the expression of Top IIβ and inducing neuronal differentiation in human MB Daoy cells. The results showed that 13-cis RA inhibited the cell proliferation and induced cell cycle arrest in G0/G1 phase. The cells differentiated into a neuronal phenotype, with high expression of the neuronal marker microtubule-associated protein 2 (MAP2) and abundant Top IIβ, and obvious neurite growth. Chromatin immunoprecipitation (ChIP) assay showed that histone H3 lysine 27 tri-methylation (H3K27me3) modification in Top IIβ promoter decreased after 13-cis RA-induced cell differentiation, while jumonji domain-containing protein 3 (JMJD3) binding in Top IIβ promoter increased. These results suggest that H3K27me3 and JMJD3 can regulate the expression of Top IIβ gene, which is related to inducing neural differentiation. Our results provide new insights into understanding the regulatory mechanisms of Top IIβ during neuronal differentiation and imply the potential application of 13-cis RA in the clinical treatment of MB.
引用
收藏
页码:7429 / 7445
页数:16
相关论文
共 256 条
  • [1] Khatua S(2018)Childhood medulloblastoma: Current therapies, emerging molecular landscape and newer therapeutic insights Current Neuropharmacology 16 1045-1058
  • [2] Song A(2021)Current treatments of medulloblastoma Current Opinion in Oncology 33 615-620
  • [3] Citla Sridhar D(2020)Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches Cancer and Metastasis Reviews 39 211-233
  • [4] Mack SC(2021)Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma Cancer Letters 499 188-200
  • [5] Beccaria K(2013)Gene regulation and priming by topoisomerase IIalpha in embryonic stem cells Nature Communications 4 2478-193
  • [6] Padovani L(2018)DNA topoisomerase IIbeta stimulates neurite outgrowth in neural differentiated human mesenchymal stem cells through regulation of Rho-GTPases (RhoA/Rock2 pathway) and Nurr1 expression Stem Cell Research & Therapy 9 114-12
  • [7] Bouchoucha Y(2014)Tetramethylpyrazine promotes SH-SY5Y cell differentiation into neurons through epigenetic regulation of Topoisomerase IIbeta Neuroscience 278 179-121
  • [8] Doz F(2018)The role of E2F1-topoIIbeta signaling in regulation of cell cycle exit and neuronal differentiation of human SH-SY5Y cells Differentiation 104 1-981
  • [9] Menyhart O(2021)Topoisomerase IIbeta immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: An immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group Brain Tumor Pathology 38 109-96
  • [10] Gyorffy B(2017)Immunohistochemical investigation of topoIIbeta, H3K27me3 and JMJD3 expressions in medulloblastoma Pathology, Research and Practice 213 975-50